Clinical Trials
3 trialsNCT06680739 2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed